Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 378-388

  Payen, S ^a   Zhang, D ^b   Maisin, A ^b   Popon, M ^b   Bensman, A ^c   Bouissou, F ^d   Loirat, C ^b   Gomeni, R ^a,e   Bressolle, Françoise ^a   Jacqz Aigrain, E ^b  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d HÔPITAL DES ENFANTS   (France)

^e GSK   (Italy)

Author keywords

Limited sampling strategy; Mycophenolate mofetil; Pediatric population; Population pharmacokinetics

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CORTICOSTEROID THERAPY; DOSE TIME EFFECT RELATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; AREA UNDER CURVE; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID;

EID: 20044390198     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000159784.25872.f6     Document Type: Article

References (55)

1. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357-1359.
2. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324.
3. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51:278-298.
4. Young CJ, Sollinger HW. RS-61443: a new immunosuppressive agent. Transplant Proc. 1994;26:3144-3146.
5. Lee HJ, Pawlak K, Nguyen BT, et al. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res. 1985;45:5512-5520.
6. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet. 1995; 345:1321-1325.
7. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
8. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232.
9. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
10. Mourad M, Wallemacq P, Konig J, et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet. 2002;41:319-327.
11. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14:353-380.
12. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
13. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 1999;21:498-506.
14. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520.
15. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
16. Hofman-La Roche, Basle, Switzerland. Data on file. 1998.
17. Filler G, Ehrich J. Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant. 1997;12:374-375.
18. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem. 1996; 42:1316-1321.
19. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit. 1995;17:685-689.
20. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol. 2000;14:95-99.
21. Filler G, Lampe D, Mai I, et al. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Transpl Int. 1998;11(Suppl 1):S82-S85.
22. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
23. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22:20-26.
24. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
25. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
26. Virji M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant. 2001;5:293-296.
27. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc. 1995;27:1421-1424.
28. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
29. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002;6:411-418.
30. Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant Proc. 1998;30:1182-1184.
31. Vinks AA. The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int J Antimicrob Agents. 2002;19:313-322.
32. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.
33. Shum R, Dufull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56:188-197.
34. Tsina I, Chu F, Hama K, et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed Appl. 1996;675:119-129.
35. Beal SL, Sheiner LB. NONMEM User's Guide. San Francisco: University of California at San Francisco, 1994.
36. Visual-NM User's Manual, Version 5.1. Montpellier, France: RDPP, 1998.
37. Wajima T, Yano Y, Oguma T. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol. 2002;54:929-934.
38. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol. 1999;51:1143-1148.
39. Roberts MS, Magnusson BM, Burczynski FJ, et al. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41:751-790.
40. Ezzet F, Krishna G, Wexler DB, et al. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther. 2001;23:871-885.
41. Pk-fit Computer Program, version 1.1. Montpellier, France: RDPP, 1997.
42. Farene C, Fabreguette JR, Bressolle F. Pk-fit: a pharmacokinetic/ pharmacodynamic and statistical data analysis software. Comput Biomed Res. 2000;33:315-330.
43. Al-Banna MK, Kelman AW, Whitng B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990;18:347-360.
44. Drusano GL. Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination. J Clin Pharmacol. 1991;31:962-967.
45. Endrenyi L. Design of experiments for estimating enzyme and pharmacokinetic experiments. In Endrenyi L, ed. Kinetic Data Analysis, Design and Analysis of Enzyme and Pharmacokinetic Experiments. New York: Plenum Press, 1981, pp 137-167.
46. Hurst AK, Yoshinaga MA, Mitani GH, et al. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother. 1990;34:1165-1171.
47. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
48. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635-651.
49. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
50. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
51. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999;21:35-43.
52. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47: 1241-1248.
53. Aigrain EJ, Shaghaghi EK, Baudouin V, et al. Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients. Transplant Proc. 2000;32:388-390.
54. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/1CH/2711/99): http://www.emea.eu.int/ pdfs/human/ich/271199EN.pdf.
55. Tett SE, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Infio J. 1998;32:693-710.